TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15369506
Drug: REMUNE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMUNE therapy every 12 weeks for 132 weeks
Study: 15369506
Drug: REMUNE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMUNE therapy
Study: 15369506
Drug: REMUNE monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REMUNE monotherapy or REMUNE plus antiretrovirals (ARTs)
Study: 9104523
Drug: 0.2 mg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg.kg-1 propofol
Study: 8251277
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with background infusion of morphine
Study: 3535990
Drug: Radiotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy followed by chemotherapy
Study: 8584072
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASS) at dosages of > or = 975 mg per day
Study: 8487136
Drug: EMLA (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (topical anesthetic)
Study: 22187234
Drug: Non-therapy control
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-therapy control
Study: 30006024
Drug: Hepatitis C-Alcohol
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention
Study: 30006024
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (TAU)
Study: 24816809
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus heparin
Study: 19875761
Drug: Anti‐CD20 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti‐CD20 monoclonal antibody therapy
Study: 19875761
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (anthracycline‐based)
Study: 15797671
Drug: Inulin-fortified beverages
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin-fortified beverages (13 g/d)
Study: 12019107
Drug: Stavudine (d4T)
Normalized name: STAVUDINE (d4T)
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) at 40 mg twice daily, 3TC at 150 mg twice daily, and indinavir at 800 mg every 8 h
Study: 8120917
Drug: GnRHA-based contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHA-based contraceptive regimen (7.5 mg leuprolide acetate depot every 28 days, 0.625 mg conjugated estrogen for 6 days each week, 10 mg medroxyprogesterone acetate for 13 days every fourth cycle)
Study: 2683658
Drug: 0.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml/kg of iohexol
Study: 2683658
Drug: 0.8 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml/kg of iohexol
Study: 1098887
Drug: Slow-release aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release aminophylline (350 mg, released over eight hours)
Study: 12379887
Drug: G-CSF treatment
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF treatment started on day 9 post transplant
Study: 2757327
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories of PDRN (10g preparation)
Study: 29331656
Drug: Optimal turning
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal turning practices influenced by real-time data from a wearable patient sensor (treatment group, n=659)
Study: 27481621
Drug: Restrictive threshold
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive threshold (transfuse if haemoglobin <7.5 g/dL)
Study: 27481621
Drug: Liberal threshold
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal threshold (transfuse if haemoglobin <9 g/dL)
Study: 12730050
Drug: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6R‐5,6,7,8‐tetrahydro‐l‐biopterin dihydrochloride (6R‐BH4; n = 10)
Study: 12730050
Drug: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6S‐5,6,7,8‐tetrahydro‐l‐biopterin sulfate (6S‐BH4; n = 10)
Study: 8633669
Drug: oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral contraceptive (50 microg ethinyl estradiol and 250 microg levonogestrel)
Study: 23009244
Drug: Home-based management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based management of malaria (HMM) using rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT)
Study: 7539184
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (alpha 1 blockade + androgen suppression)
Study: 1899776
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of recombinant tissue-type plasminogen activator (rt-PA)
Study: 27261222
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) after a withdrawal bleed induced by Medroxyprogesterone Acetate (MPA) 10 mg daily for 10 days
Study: 27261222
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) without a preceding withdrawal bleed
Study: 21258125
Drug: Thyroxine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine (50 µg daily, increased as necessary)
Study: 8493493
Drug: Glucose-insulin-potassium infusion
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium infusion (0.5 g glucose, 1.35 IU insulin, 0.25 mmol/kg b.w/hour)
Study: 1637215
Drug: Glucose-insulin-potassium infusion
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium infusion
Study: 8493493
Drug: Glucose-insulin-potassium infusion
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium infusion and Control group
Study: 3121928
Drug: Naloxone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (4 mg bolus followed by 2 mg/h infusion for 4 h)
Study: 24347426
Drug: Estrogen administration
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen administration
Study: 8638453
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS) in 20 ml of 5% dextrose
Study: 8638453
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 5% dextrose (control)
Study: 8638453
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous dehydroepiandrosterone sulfate (DHAS)
Study: 1365017
Drug: G‐CSF in
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF in patients receiving positively selected marrow
Study: 31721670
Drug: Negative wound
Normalized name: Microcyn Negative Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative wound pressure therapy (NPWT)
Study: 20158620
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (2 microg x kg(‐1)) + caudal 0.25% levobupivacaine
Study: 16273784
Drug: Disease modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease modifying drugs and biologic agents
Study: 371056
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg salbutamol solution
Study: 3291074
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ivermectin (150 micrograms/kg)
Study: 1867345
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of ivermectin (150 micrograms/kg) at 6-month intervals
Study: 6354826
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (800 mg/day)
Study: 29728334
Drug: Alprostadil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil (2 μg by intracoronary infusion)
Study: 29728334
Drug: Nitroglycerin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (200 μg)
Study: 26556733
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid infusion
Study: 23788684
Drug: Denosumab injection
Normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab injection
Study: 19022156
Drug: Statins (3‐hydroxy‐3‐methyl‐glutaryl‐CoA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (3‐hydroxy‐3‐methyl‐glutaryl‐CoA reductase inhibitors)
Study: 11032464
Drug: Amisulpride (400-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400-1200 mg/d)
Study: 1940446
Drug: Low-dose UVB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UVB exposure
Study: 30089292
Drug: Electrical acupuncture
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrical acupuncture with oral essential amino acids (EA + AA)
Study: 30089292
Drug: Oral essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral essential amino acids alone (AA)
Study: 16164495
Drug: Midazolam maintenance
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam maintenance dose ranging from 37.5 to 100 microg/kg/h
Study: 15314976
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with Vepesid and Cisplatin
Study: 3336380
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum
Study: 8916629
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg nicotine gum (placebo)
Study: 24274627
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment differences
Study: 2008293
Drug: 1% hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hyaluronan (Healon; HYA) instilled once daily for 7 days
Study: 6998553
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum immunotherapy
Study: 7037155
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment alone (Control)
Study: 1617888
Drug: Surfactant replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant replacement therapy
Study: 30974433
Drug: Caffeine and
Normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine and postnatal steroids
Study: 27735908
Drug: Serum soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with poor course of CHF (n=45)
Study: 27735908
Drug: Serum soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum soluble Fas ligand (sFas-L) levels measured by enzyme immunoassay in patients with favorable course of CHF (n=49)
Study: 27735908
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of baseline sFas-L levels between CHF patients and control group
Study: 27735908
Drug: ROC analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROC analysis of sFas-L levels for cardiovascular risk stratification
Study: 27735908
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of left ventricular (LV) ejection fraction with sFas-L concentrations
Study: 19067472
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg once daily for 3 days
Study: 19067472
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg single dose
Study: 19067472
Drug: Prulifloxacin 600
Normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prulifloxacin 600 mg repeated dosing
Study: 16103328
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod cream applied 3 times a week for 16 weeks
Study: 12065555
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (cisplatin and continuous-infusion doxorubicin)
Study: 2533616
Drug: Nafarelin, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafarelin, a gonadotropin releasing hormone analog, dosage and duration not specified.
Study: 31830347
Drug: TPF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF (docetaxel 60 mg/m2, cisplatin 60 mg/m2, 5-FU 750 mg/m2 continuous IV infusion)
Study: 31830347
Drug: PF (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF (cisplatin 75 mg/m2, 5-FU 750 mg/m2)
Study: 25426701
Drug: Neutral protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral protamine Hagedorn (NPH) insulin
Study: 28040350
Drug: Overall population
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall population (all insulin regimens)
Study: 26063677
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 40-60 mg/day for 4 weeks
Study: 19966380
Drug: De Marco
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De Marco Formula (DMF) 15 ml/kg .day i.m. for 10 days, then twice a week until healing or completion of 52 days
Study: 11697810
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate + 500 mg calcium (n = 8)
Study: 11697810
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg calcium only (n = 5)
Study: 9134641
Drug: Heparin bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin bolus during PTCA
Study: 3130756
Drug: Single-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefazolin (1 gm intravenous)
Study: 3130756
Drug: Three-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-dose cefazolin (1 gm intravenous followed by two additional doses, 8 hours apart)
Study: 30027615
Drug: Single-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefazolin
Study: 3130756
Drug: Three-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-dose cefazolin
Study: 26681680
Drug: S-1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 monotherapy
Study: 16430743
Drug: OraDisc (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OraDisc (2 mg amlexanox), applied four times a day for 72 hours
Study: 16430743
Drug: Vehicle patches,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle patches, applied four times a day for 72 hours
Study: 16430743
Drug: OraDisc (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OraDisc (2 mg amlexanox)
Study: 15251640
Drug: Strict insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Strict insulin therapy (target glucose range, 80 to 120 mg/dL)
Study: 11421871
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no octreotide treatment)
Study: 7870912
Drug: oxiracetam 800
Normalized name: oxiracetam 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxiracetam 800 mg
Study: 7870912
Drug: oxiracetam 2400
Normalized name: oxiracetam
DrugBank: Oxiracetam (DB13601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxiracetam 2400 mg
Study: 26578119
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg administered 1 hour before and 1 hour after surgery
Study: 22497680
Drug: A priori
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A priori heparin administration (50 IU/kg) immediately after sheath insertion
Study: 22497680
Drug: Provisional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provisional heparin use only if radial artery patency could not be maintained, otherwise no heparin given during the procedure, with a bolus of heparin (50 IU/kg) if needed
Study: 1424183
Drug: Selenium 50
Normalized name: SELENIUM 50MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 50 micrograms as selenomethionine administered once daily for 2 months
Study: 3659581
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol
Study: 2934747
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipratropium and fenoterol
Study: 27306219
Drug: Cystine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine (700 mg) and theanine (280 mg) orally 1 week before and during S-1 chemotherapy for 5 weeks.
Study: 27306219
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving S-1 chemotherapy without cystine and theanine.
Study: 18601306
Drug: dexmethylphenidate ER
Normalized name: dexmethylphenidate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmethylphenidate ER 20 mg/day
Study: 15816453
Drug: PEG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG plus cisapride (10 mg per os thrice per day three days before the procedure and one 10-mg dose on the morning of the procedure)
Study: 12808585
Drug: Conjoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint therapy for partners of alcohol abusers
Study: 12808585
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of patient-treatment matching dimensions
Study: 12740337
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg once daily
Study: 28587568
Drug: Collagenase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase treatment
Study: 11143848
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with very high lipoprotein (a) levels (> 40 mg/dl)
Study: 6711776
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine hydrochloride bolus followed by continuous morphine infusion at 0.16 mg/hour
Study: 6711776
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of 2.3 +/- 0.6 mg morphine hydrochloride until the end of the operation
Study: 27526979
Drug: Rifampicin 900
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 900 mg orally
Study: 27526979
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg intravenously (i.v.)
Study: 27526979
Drug: Rifampicin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (all doses)
Study: 18656091
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg daily
Study: 3555050
Drug: Beta-lactam antibiotics
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam antibiotics
Study: 8891854
Drug: Conventional plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional plus L-dopa treatment
Study: 27472747
Drug: Structured Approach
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Approach Therapy (SAT)
Study: 21971213
Drug: Capsaicin 15
Normalized name: CAPSAICIN 150 mg in 100000 mg TOPICAL LIQUID [Good Neighbor Pharmacy Capsaicin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 15 mg (Anesiva 4975) instillation
Study: 18273636
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment arm
Study: 20649635
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg daily)
Study: 8448974
Drug: Intravenous [14C]omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous [14C]omeprazole 20mg
Study: 8448974
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution [14C]omeprazole 40mg
Study: 1385147
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy for BPH
Study: 1385147
Drug: Drug trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug trial
Study: 22809684
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting injection (RLAI)
Study: 1813168
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) and clomiphene
Study: 6994779
Drug: Methyldopa 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa 1.2 g daily
Study: 30866859
Drug: Intervention with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention with print educational materials and Fitbit Flex™ and daily text messages